Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HARMONi-6: Ivonescimab vs Tislelizumab in 1L Squamous NSCLC
NCT05840016Phase 3Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Aug 2023
- Primary completion
- Feb 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ivonescimab in squamous cell carcinoma of the lung (SCCL) (2 arms), sponsored by Akeso, Inc. Primary endpoint: Progression-Free Survival. Started Aug 2023; status: active, not recruiting.
02
Drugs
ivonescimab
03
Conditions
squamous cell carcinoma of the lung (SCCL)
Beyond the preview
Go deeper on NCT05840016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05840016.